Article in ERJ open research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 3 institutions in 2 countries.
Maria J GutierrezDivision of Pediatric Allergy, Immunology and Rheumatology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID https://orcid.org/0000-0001-5494-5841
Gustavo NinoDivision of Pulmonary and Sleep Medicine, Children's National Hospital, George Washington University, Washington, DC, USA.
Elizabeth ChorvinskyCenter for Genetic Medicine Research, Children's Research Institute, Washington, DC, USA.
Surajit BhattacharyaCenter for Genetic Medicine Research, Children's Research Institute, Washington, DC, USA.
Bethlehem Solomon BeraCenter for Genetic Medicine Research, Children's Research Institute, Washington, DC, USA.
Allison WelhamCenter for Genetic Medicine Research, Children's Research Institute, Washington, DC, USA.
Xiumei HongCenter on the Early Life Origins of Disease, Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Xiaobin WangCenter on the Early Life Origins of Disease, Department of Population, Family and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Johns Hopkins University · USChildren's National · USUniversidad Nacional de Colombia · CO
Funding
Preterm Birth, Maternal and Cord Blood Metabolome, and Child Metabolic RiskR01HD041702 · NICHD · LURIE CHILDREN'S HOSPITAL OF CHICAGO · PI Frank B Hu, XIAOBIN WANG · 2001 to 2026
$11.1M
Immune Development Across the Life Course: Integrating Exposures and Multi-Omics in the Boston Birth CohortU01ES034983 · NIEHS · JOHNS HOPKINS UNIVERSITY · PI Hongkai Ji, Harry Benjamin Larman · 2022 to 2026
$3.9M
Early Life Determinants of Obesity in U.S. Urban Low Income Minority Birth CohortR01HD086013 · NICHD · JOHNS HOPKINS UNIVERSITY · PI LEE, BRUCE Y, WANG, XIAOBIN · 2016 to 2020
$3.3M
The Hopkins Population CenterP2CHD042854 · NICHD · JOHNS HOPKINS UNIVERSITY · PI Alison Gemmill · 2021 to 2026
$3.0M
Functional RNA Modifications, Micronutrient Exposure, Developmental DisabilitiesR01ES031521 · NIEHS · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI WANG, XIAOBIN, XIE, HEHUANG · 2020 to 2024
$1.9M
Maternal Exposure to Low Level Mercury, Metabolome, and Child Cardiometabolic Risk in Multi-Ethnic Prospective Birth CohortsR01ES031272 · NIEHS · JOHNS HOPKINS UNIVERSITY · PI WANG, GUOYING, WANG, XIAOBIN · 2020 to 2024
$1.2M
“Role of Maternal Obesity in Epigenetic and Metabolic Programming and Lower Respiratory Infection Risk in Early Life” K23HD104933 · NICHD · JOHNS HOPKINS UNIVERSITY · PI GUTIERREZ, MARIA JIMENA · 2021 to 2025
$854k
Maternal and Cord Blood Metabolome, Infant Feeding, and Development of Food Allergy in a Prospective Birth CohortR21AI154233 · NIAID · JOHNS HOPKINS UNIVERSITY · PI HONG, XIUMEI · 2020 to 2021
Background: Lower respiratory tract infections (LRTIs) are the leading cause of infant morbidity and mortality worldwide, and altered metabolite production is recognised as a critical factor in LRTI pathogenesis. Methods: This study aimed to identify prenatal metabolic changes associated with LRTI risk in infancy, using liquid chromatography-mass spectrometry unbiased metabolomics analysis on cord blood from 810 full-term newborns. Results: We identified 22 compounds linked to LRTIs in infancy, enriched for purine degradation pathway (PDP) metabolites. High cord blood PDP metabolites, including xanthine, hypoxanthine, xanthosine and inosine, were linked to reduced LRTI risk during infancy. Notably, a low xanthine to uric acid ratio at birth predicted a four-fold increased LRTI risk. Conclusion: This study is the first to reveal that high cord blood PDP metabolites identify newborns at lower LRTI risk, stratifying disease risk at birth. Moreover, our results prompt further study on PDP enzymes as pharmacological targets to decrease LRTI morbidity and mortality for at-risk newborns.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Purine degradation pathway metabolites at birth and the risk of lower respiratory tract infections in infancy. · full record | OpenQuestion